Vertex Pharmaceuticals Inc / Ma: Form 10-Q for the period ended Mar 31, 2012
Filed with the SEC on May 10, 2012 and accepted by EDGAR at May 10, 2012, 20:17 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2012-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2012-01-01 to 2012-03-31 | $438.7m | us-gaap:Revenues |
| Cost of revenue | 3 months2012-01-01 to 2012-03-31 | $25.9m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2012-01-01 to 2012-03-31 | $196.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2012-01-01 to 2012-03-31 | $111.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2012-01-01 to 2012-03-31 | $91.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2012-01-01 to 2012-03-31 | $4.1m | us-gaap:InterestExpense |
| Income tax | 3 months2012-01-01 to 2012-03-31 | $32.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2012-01-01 to 2012-03-31 | $91.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2012-01-01 to 2012-03-31 | $0.43 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2012-01-01 to 2012-03-31 | $0.44 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2012-01-01 to 2012-03-31 | 219,264,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 3 months2012-01-01 to 2012-03-31 | $6.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2012-03-31 | $267.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2012-03-31 | $1.44bn | us-gaap:AssetsCurrent |
| Total assets | At period end2012-03-31 | $2.35bn | us-gaap:Assets |
| Current liabilities | At period end2012-03-31 | $356.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2012-03-31 | $1.24bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2012-03-31 | $930.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001047469-12-005755. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.